HR7385-119

In Committee

PrEP Assistance Program Act

119th Congress Introduced Feb 4, 2026

Summary

What This Bill Does

The PrEP Assistance Program Act directs HHS, through CDC and HRSA, to establish PrEP grants within one year for eligible entities such as states, local governments, Indian Tribal governments, FQHCs, rural health clinics, community-based organizations, hospital-based clinics, and university-based clinics. Grants are capped at $10 million, prioritize entities serving communities with disproportionately high HIV incidence or using innovative models like vending machines, pop-up clinics, and peer-led interventions, and may pay for clinic and lab fees, telehealth visits, PrEP medication, blood and urine testing, STI testing, adherence counseling, outreach, peer navigation, case management, transportation, and mental-health services. The bill also creates a HRSA reimbursement program and a PrEP Pass for uninsured individuals, with provider claims paid at HHS-set rates and no cost-sharing for covered prevention services.

Who Benefits and How

Uninsured people at risk of HIV, rural residents, high-incidence communities, and demographic groups with elevated HIV risk benefit from free PrEP medication and wraparound prevention services. FQHCs, rural health clinics, community-based organizations, hospitals, university clinics, states, local governments, and Indian Tribal governments benefit from grant funding and a provider reimbursement path. PrEP drug manufacturers, labs, and prevention providers may see more paid utilization.

Who Bears the Burden and How

HHS, CDC, and HRSA must build grant rules, provider registration, PrEP Pass technology, provider payment amounts, eligible-expense lists, public reports, and disaggregated impact data. Most grantees must contribute a 10 percent match unless they are tribal governments or receive a waiver. Program-registered providers must agree not to bill uninsured individuals for reimbursed PrEP items and services. Federal taxpayers fund the $400 million annual authorization for fiscal years 2027 through 2031 and any reimbursements subject to appropriations.

Key Provisions

  • Creates CDC-HRSA PrEP grants capped at $10 million per eligible entity for states, localities, tribes, FQHCs, rural clinics, community organizations, hospitals, and university clinics.
  • Authorizes grant spending for PrEP medication, labs, telehealth, STI testing, counseling, outreach, peer navigation, case management, transportation, and mental-health support.
  • Requires covered PrEP items and services to be free to individuals served by grant-supported programs.
  • Creates a HRSA reimbursement program and PrEP Pass so uninsured individuals can obtain specified HIV prevention services at no cost.
  • Authorizes $400 million annually for fiscal years 2027 through 2031 and requires public impact reports with race, gender identity, age, and geography data.

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

Creates HHS grant and reimbursement programs to make HIV pre-exposure prophylaxis medications, labs, counseling, and related prevention services available at no cost, especially for uninsured and high-risk communities.

Key Policy Areas

Healthcare, Pharmaceuticals, Social Services

Primary Purpose

Creates HHS grant and reimbursement programs to make HIV pre-exposure prophylaxis medications, labs, counseling, and related prevention services available at no cost, especially for uninsured and high-risk communities.

Policy Domains

Healthcare Pharmaceuticals Social Services

Substantive provisions

Identified Gains
  • Uninsured people at risk of HIV
  • FQHCs
  • Rural health clinics
  • Community based organizations
  • Indian Tribal governments
  • PrEP drug manufacturers
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih
FQHCs: ,
Rural health clinics: ,
PrEP drug manufacturers: ,
Indian Tribal governments: ,
Community based organizations: ,
Uninsured people at risk of HIV: ,
Identified Costs
  • HHS
  • CDC
  • HRSA
  • Grant recipients
  • Program registered providers
  • Federal taxpayers
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih
CDC: ,
HHS: ,
HRSA: ,
Grant recipients: ,
Federal taxpayers: ,
Program registered providers: ,

Legislative Progress

In Committee
Introduced Committee Passed
Feb 4, 2026

Referred to the House Committee on Energy and Commerce.

Feb 4, 2026

Introduced in House

Feb 4, 2026

Mrs. Watson Coleman (for herself, Mr. Carson, Ms. Waters, Ms. …

Stakeholder Effects

cui bono?

How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.

Healthcare
7 mentions across 2 clauses
+4 positive -3 negative

FQHCs, Grant recipients, HHS

Positive-direction: FQHCs, Program registered providers, Uninsured people at risk of HIV

Negative-direction: Grant recipients, HHS, HRSA

Taxpayers
2 mentions across 2 clauses
-2 negative

Taxpayers

Tribal Nations
1 mention across 1 clause
+1 positive

Indian Tribal governments

Pharmaceuticals
1 mention across 1 clause
+1 positive

PrEP drug manufacturers

2/3
sections analyzed
Full impact breakdown

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Healthcare Pharmaceuticals Social Services
Actor Mappings
"cdc"
→ Centers for Disease Control and Prevention
"hrsa"
→ Health Resources and Services Administration
"secretary"
→ HHS Secretary

Key Definitions

Terms defined in this bill

1 term
"specified HIV prevention items and services" §3

FDA-approved HIV-prevention drugs including PrEP, administrative fees, and CDC-recommended laboratory or diagnostic procedures associated with PrEP use.

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology